Implantable infusion devices with closed loop sensing and associated methods

US2021121624A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2021121624-A1
Application numberUS-202017078816-A
CountryUS
Kind codeA1
Filing dateOct 23, 2020
Priority dateOct 23, 2019
Publication dateApr 29, 2021
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Implantable infusion devices and methods that provide closed loop control.

First claim

Opening claim text (preview).

We claim: 1 . A method, comprising the steps of: delivering pain medication to a patient with an implantable infusion device; monitoring biometric data of the patient with a patient monitor; determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of an opioid overdose; and immediately ending delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of an opioid overdose. 2 . A method as claimed in claim 1 , further comprising the step of: transmitting an opioid overdose alert in response to a determination by the implantable infusion device that the monitored biometric data is indicative of an opioid overdose. 3 . A method as claimed in claim 1 , wherein the monitored biometric data comprises one or more of respiration rate, blood oxygen saturation (SpO2), blood pressure, body temperature, heart rate, heart rate variability, accelerometer data, skin conductance, EMG, EEG and facial expressions. 4 . A method as claimed in claim 1 , wherein the implantable infusion device includes housing, a reservoir within the housing, and a fluid transfer device within the housing; and monitoring biometric data comprises monitoring biometric with a sensor that is within the housing. 5 . A method as claimed in claim 1 , wherein monitoring biometric data comprises monitoring biometric data with a body worn sensor; and the method further comprises wirelessly transmitting the monitored biometric data from the body worn sensor to the implantable infusion device. 6 . A method as claimed in claim 1 , further comprising the steps of determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of pain above a predetermined threshold; and increasing delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of pain above the predetermined threshold. 7 . An implantable infusion device, comprising: an outlet port configured to be secured to a catheter; a reservoir configured to store an infusible substance; a fluid transfer device, operably connected to the reservoir and outlet port, configured to transfer the infusible substance from the reservoir to the outlet when actuated; and a controller, operably connected to the fluid transfer device, configured to actuate the fluid transfer device in accordance with a stored delivery profile, to receive monitored biometric data, to determine whether or not the monitored biometric data is indicative of an opioid overdose, and to immediately end actuation of the fluid transfer device in response to a determination by the controller that the monitored biometric data is indicative of an opioid overdose. 8 . An implantable infusion device as claimed in claim 7 , further comprising: a wireless communication device operably connected to the controller; wherein the controller is configured to transmit an opioid overdose alert by way of the wireless communication device in response to a determination that the monitored biometric data is indicative of an opioid overdose. 9 . An implantable infusion device as claimed in claim 7 , wherein the monitored biometric data comprises one or more of respiration rate, blood oxygen saturation (SpO2), blood pressure, body temperature, heart rate, heart rate variability, accelerometer data, skin conductance, EMG, EEG and facial expressions. 10 . An implantable infusion device as claimed in claim 7 , further comprising; a housing in which the reservoir and fluid transfer device are located; and a sensor configured to monitor biometric data located within the housing and operably connected to the controller. 11 . An implantable infusion device as claimed in claim 7 , further comprising: a wireless communication device operably connected to the controller; wherein the controller is configured to receive the biometric data by way of the wireless communication device. 12 . An implantable infusion device as claimed in claim 7 , wherein the controller is configured to determine whether or not the monitored biometric data is indicative of pain above a predetermined level and to increase actuation of the fluid transfer device in response to a determination by the controller that the monitored biometric data is indicative of pain above the predetermined level. 13 . A method, comprising the steps of: delivering pain medication to a patient with an implantable infusion device; monitoring biometric data of the patient with a patient monitor; determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of pain above a predetermined threshold; and increasing delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of pain above the predetermined threshold. 14 . A method as claimed in claim 13 , wherein the monitored biometric data comprises one or more of nerve activity, muscle activity, chemical signals, respiration rate, blood pressure, body temperature, heart rate, and heart rate variability. 15 . A method as claimed in claim 13 , wherein the implantable infusion device includes housing, a reservoir within the housing, and a fluid transfer device within the housing; and monitoring biometric data comprises monitoring biometric with a sensor that is within the housing. 16 . A method as claimed in claim 13 , wherein monitoring biometric data comprises monitoring biometric data with a body worn sensor; and the method further comprises wirelessly transmitting the monitored biometric data from the body worn sensor to the implantable infusion device. 17 . A method as claimed in claim 13 , wherein monitoring biometric data comprises monitoring biometric data with a sensor on a catheter. 18 . A method as claimed in claim 13 , further comprising the steps of determining, with the implantable infusion device, whether or not the monitored biometric data is indicative of an opioid overdose; and immediately ending delivery of the pain medication with the implantable infusion device in response to a determination by the implantable infusion device that the monitored biometric data is indicative of an opioid overdose. 19 . An implantable infusion device, comprising: an outlet port configured to be secured to a catheter; a reservoir configured to store an infusible substance; a fluid transfer device, operably connected to the reservoir and outlet port, configured to transfer the infusible substance from the reservoir to the outlet when actuated; and a controller, operably connected to the fluid transfer device, configured to actuate the fluid transfer device in accordance with a stored delivery profile, to receive monitored biometric data, to determine whether or not the monitored biometric data is indicative of pain above a predetermined level, and to increase delivery of the infusible substance in response to a determination by the controller that the monitored biometric data is indicative of pain above the predetermined level. 20 . An implantable infusion device as claimed in claim 19 , wherein the monitored biometric data comprises one or more of nerve activity, muscle activity,

Assignees

Inventors

Classifications

  • specially adapted for implantation · CPC title

  • Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches · CPC title

  • Using a biosensor · CPC title

  • remote, e.g. between patient's home and doctor's office · CPC title

  • with alarm · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2021121624A1 cover?
Implantable infusion devices and methods that provide closed loop control.
Who is the assignee on this patent?
The Alfred E Mann Foundation For Scient Research
What technology area does this patent fall under?
Primary CPC classification A61M5/14276. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Apr 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).